Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001

NCT02655601 is registered in ClinicalTrials.gov with BioMimetix JV, LLC as lead sponsor.

NCT NCT02655601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02655601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Lead sponsor
BioMimetix JV, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
September 25, 2018
Completion date
December 31, 2024
Enrollment
177 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iii, glioblastoma, high grade glioma